Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting

Clinics and Research in Hepatology and Gastroenterology, Год журнала: 2025, Номер unknown, С. 102581 - 102581

Опубликована: Март 1, 2025

Язык: Английский

---

Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(7), С. 2441 - 2441

Опубликована: Апрель 3, 2025

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition worldwide, with significant regional variability in prevalence estimates. This study aimed to determine the prevalence, demographic characteristics, and economic burden of MASLD, metabolic (MASL), steatohepatitis (MASH) Valencian Community region Spain. Methods: We conducted retrospective analysis electronic medical records from public healthcare database individuals aged over 24 years 2012 2019. Results: Of 3,411,069 included 2019, 75,565 were diagnosed 74,065 MASL, 1504 MASH based on International Classification Diseases (ICD), corresponding 2.22%, 2.17%, 0.04%, respectively. Among type 2 diabetes mellitus (T2DM) or obesity, MASLD was approximately three times 2.5 higher, respectively, compared overall population. The increased 2019 all populations studied. highest risk hospitalization associated liver-related causes, followed by all-cause hospitalization. cost per subject observed concomitant T2DM. Conclusions: Our findings indicate rising MASH, despite their potential underdiagnosis during period. presence high costs, particularly patients results underline need for more effective strategies enhance awareness improve resource allocation.

Язык: Английский

---

Prediction of major liver-related events in the population using prognostic models

Gastroenterology report, Год журнала: 2025, Номер 13

Опубликована: Янв. 1, 2025

Abstract Liver disease poses a significant global health burden, with steatotic liver related to metabolic dysfunction and/or alcohol use being the most prevalent type. Current risk stratification strategies emphasize detecting advanced fibrosis as surrogate marker for liver-related events (LREs), such hospitalization, cancer, or death. However, alone does not adequately predict imminent outcomes, particularly in fast-progressing individuals without at evaluation. This underscores need models designed specifically LREs, enabling timely interventions. The Chronic Disease (CLivD) score, dynamic aspartate aminotransferase-to-alanine aminotransferase ratio (dAAR), and Cirrhosis Outcome Risk Estimator (CORE) were explicitly developed LRE rather than detect fibrosis. Derived from general population cohorts, these incorporate either standard enzymes (dAAR CORE) factors (CLivD), broad application primary care population-based settings. They directly estimate of future improving on traditional fibrosis-focused approaches. Conversely, widely used like Fibrosis-4 index newer ones, LiverRisk LiverPRO scores, initially significant/advanced stiffness. While prediction, they have later been analyzed this purpose. Integrating screening LRE-focused CLivD, dAAR, CORE can help healthcare systems adopt proactive, preventive care. approach emphasizes identifying severe potentially ensuring better resource allocation personalized

Язык: Английский

---

Preface

Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(Suppl), С. S3 - S3

Опубликована: Авг. 11, 2024

---